Johnson Britt A, Dajnoki Angela, Bodamer Olaf A
Division of Clinical and Translational Genetics, Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida.
Curr Protoc Hum Genet. 2015 Jan 20;84:17.17.1-17.17.8. doi: 10.1002/0471142905.hg1717s84.
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder due to deficiency of alpha iduronidase (IDUA). Progressive storage of dermatan and heparan sulfate throughout the body lead to a multiorgan presentation including short stature, dysostosis multiplex, corneal clouding, hearing loss, coarse facies, hepatosplenomegaly, and intellectual disability. Diagnosis of MPS I is based on IDUA enzyme analysis in leukocytes or dried blood spots (DBS) followed by molecular confirmation of the IDUA gene mutations in individuals with low enzyme activity. The advent of mass spectrometry methods for enzyme analysis in DBS has enabled high-throughput screening for MPS I in symptomatic individuals and newborn infants. The following unit provides the detailed analytical protocol for measurement of IDUA activity in DBS using tandem mass spectrometry.
I型黏多糖贮积症(MPS I)是一种由于α-L-艾杜糖醛酸酶(IDUA)缺乏引起的溶酶体贮积症。硫酸皮肤素和硫酸乙酰肝素在全身进行性蓄积,导致多器官受累,表现为身材矮小、多发性骨发育异常、角膜混浊、听力丧失、面容粗糙、肝脾肿大和智力残疾。MPS I的诊断基于白细胞或干血斑(DBS)中的IDUA酶分析,随后对酶活性低的个体进行IDUA基因突变的分子确认。用于DBS中酶分析的质谱方法的出现,使得能够对有症状个体和新生儿进行MPS I的高通量筛查。以下单元提供了使用串联质谱法测量DBS中IDUA活性的详细分析方案。